Literature DB >> 28750193

Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.

Seonaid Nolan1,2, Jane Buxton3,4, Sabina Dobrer1, Huiru Dong1, Kanna Hayashi1,2, M J Milloy1,2, Thomas Kerr1,2, Julio Montaner1,2, Evan Wood1,2.   

Abstract

OBJECTIVES: Although take-home naloxone (THN) programs are integral in strategies to prevent overdose deaths among opioid users, the uptake of THN among people who use drugs (PWUD) (including non-opioid users) is unknown. The objectives of this study were to determine awareness, possession, and use of THN among PWUD in Vancouver, Canada, and identify barriers to adopting this strategy.
METHODS: From December 1, 2014, to May 29, 2015, participants in 2 prospective cohort studies of PWUD in Vancouver completed a standardized questionnaire, which asked about awareness, possession, and use of THN; sociodemographic characteristics; and drug use patterns. We conducted multivariable logistic regression analyses to determine factors independently associated with awareness and possession of THN.
RESULTS: Of 1137 PWUD, 727 (64%) reported at least 1 previous overdose ever, and 220 (19%) had witnessed an overdose in the previous 6 months. Although 769 (68%) participants overall reported awareness of THN, only 88 of 392 (22%) opioid users had a THN kit, 18 (20%) of whom had previously administered naloxone. Factors that were positively associated with awareness of THN included witnessing an overdose in the previous 6 months (adjusted odds ratio [aOR] = 2.23; 95% confidence interval [CI], 1.49-3.34; P < .001), possession of THN (aOR = 1.85; 95% CI, 1.11-3.06; P = .02), younger age (aOR = 1.02; 95% CI, 1.01-1.04; P = .003), white race (aOR = 1.67; 95% CI, 1.27-2.19; P < .001), hepatitis C infection (aOR = 1.63; 95% CI, 1.13-2.36; P = .01), residing in Vancouver's Downtown Eastside neighborhood (aOR = 1.93; 95% CI, 1.47-2.53; P < .001), and at least daily heroin injection (aOR = 1.69; 95% CI, 1.09-2.62; P < .02).
CONCLUSION: Efforts to improve knowledge of and participation in the THN program may contribute to reduced opioid overdose mortality in Vancouver.

Entities:  

Keywords:  illicit drug use; naloxone; opioid overdose; opioids; take-home naloxone

Mesh:

Substances:

Year:  2017        PMID: 28750193      PMCID: PMC5593231          DOI: 10.1177/0033354917717230

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  19 in total

1.  Staging for antiretroviral therapy among HIV-infected drug users.

Authors:  Evan Wood; Robert S Hogg; Simon Bonner; Thomas Kerr; Kathy Li; Anita Palepu; Silvia Guillemi; Martin T Schechter; Julio S G Montaner
Journal:  JAMA       Date:  2004-09-08       Impact factor: 56.272

Review 2.  Prescription opioid related misuse, harms, diversion and interventions in Canada: a review.

Authors:  Benedikt Fischer; Elena Argento
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

3.  Use and nonmedical use of prescription opioid analgesics in the general population of Canada and correlations with dispensing levels in 2009.

Authors:  Kevin D Shield; Wayne Jones; Jürgen Rehm; Benedikt Fischer
Journal:  Pain Res Manag       Date:  2013 Mar-Apr       Impact factor: 3.037

4.  A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program.

Authors:  Oluwajenyo Banjo; Despina Tzemis; Diana Al-Qutub; Ashraf Amlani; Sarah Kesselring; Jane A Buxton
Journal:  CMAJ Open       Date:  2014-07-22

5.  Barriers to use of free antiretroviral therapy in injection drug users.

Authors:  S A Strathdee; A Palepu; P G Cornelisse; B Yip; M V O'Shaughnessy; J S Montaner; M T Schechter; R S Hogg
Journal:  JAMA       Date:  1998-08-12       Impact factor: 56.272

6.  Experience of non-fatal overdose among heroin users in Adelaide, Australia: circumstances and risk perceptions.

Authors:  C McGregor; S Darke; R Ali; P Christie
Journal:  Addiction       Date:  1998-05       Impact factor: 6.526

7.  Findings and lessons learnt from implementing Australia's first health service based take-home naloxone program.

Authors:  Karen J Chronister; Nicholas Lintzeris; Anthony Jackson; Mihaela Ivan; Paul M Dietze; Simon Lenton; John Kearley; Ingrid van Beek
Journal:  Drug Alcohol Rev       Date:  2016-04-13

8.  Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study.

Authors:  Nancy Worthington; Tinka Markham Piper; Sandro Galea; David Rosenthal
Journal:  Harm Reduct J       Date:  2006-07-05

9.  "We don't need services. We have no problems": exploring the experiences of young people who inject drugs in accessing harm reduction services.

Authors:  Anita Krug; Mikaela Hildebrand; Nina Sun
Journal:  J Int AIDS Soc       Date:  2015-02-26       Impact factor: 5.396

Review 10.  Providing comprehensive health services for young key populations: needs, barriers and gaps.

Authors:  Sinead Delany-Moretlwe; Frances M Cowan; Joanna Busza; Carolyn Bolton-Moore; Karen Kelley; Lee Fairlie
Journal:  J Int AIDS Soc       Date:  2015-02-26       Impact factor: 5.396

View more
  8 in total

1.  Racial differences in overdose training, naloxone possession, and naloxone administration among clients and nonclients of a syringe services program.

Authors:  A A Jones; J N Park; S T Allen; K E Schneider; B W Weir; D Hunt; S G Sherman
Journal:  J Subst Abuse Treat       Date:  2021-04-15

2.  Knowledge and possession of take-home naloxone kits among street-involved youth in a Canadian setting: a cohort study.

Authors:  Julia Goldman-Hasbun; Kora DeBeck; Jane A Buxton; Ekaterina Nosova; Evan Wood; Thomas Kerr
Journal:  Harm Reduct J       Date:  2017-12-22

3.  Lay responder naloxone access and Good Samaritan law compliance: postcard survey results from 20 Indiana counties.

Authors:  Dennis P Watson; Bradley Ray; Lisa Robison; Philip Huynh; Emily Sightes; La Shea Walker; Krista Brucker; Joan Duwve
Journal:  Harm Reduct J       Date:  2018-04-06

4.  Naloxone distribution and possession following a large-scale naloxone programme.

Authors:  Desiree Madah-Amiri; Linn Gjersing; Thomas Clausen
Journal:  Addiction       Date:  2018-09-14       Impact factor: 6.526

5.  Justice involvement patterns, overdose experiences, and naloxone knowledge among men and women in criminal justice diversion addiction treatment.

Authors:  Rachel E Gicquelais; Briana Mezuk; Betsy Foxman; Laura Thomas; Amy S B Bohnert
Journal:  Harm Reduct J       Date:  2019-07-16

6.  Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland.

Authors:  Megan Buresh; Rachel E Gicquelais; Jacquie Astemborski; Gregory D Kirk; Shruti H Mehta; Becky L Genberg
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.752

7.  Intention to get naloxone among patients prescribed opioids for chronic pain.

Authors:  Yinan Huang; Ning Lyu; Shrey Gohil; Shweta Bapat; E James Essien; J Douglas Thornton
Journal:  Harm Reduct J       Date:  2022-09-22

8.  Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study.

Authors:  Lauren Lipira; Gillian Leichtling; Ryan R Cook; Judith M Leahy; E Roberto Orellana; P Todd Korthuis; Timothy W Menza
Journal:  Drug Alcohol Depend       Date:  2021-07-21       Impact factor: 4.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.